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A B S T R A C T
Introduction: Successful vaccination of elderly persons is often hampered by immunological ageing, leaving part
of the elderly population vulnerable for infectious diseases. As an alternative, timely vaccinations might be
administered at middle-age, before reaching old age. Studies evaluating the immunological ﬁtness of middle-
aged adults are warranted. In this study we compared the immunogenicity of a primary meningococcal vacci-
nation in Dutch middle-aged adults with that in adolescents, in order to gain knowledge on the early signs of
immune ageing.
Methods: In this study, we compared the antibody responses after a primary meningococcal vaccination between
middle-aged adults (50–65 years of age, N= 204) and adolescents (10–15 years of age, N= 225). Blood sam-
ples were taken pre-, as well as 28 days and 1 year post-vaccination. Functional antibody titers were measured
with the serum bactericidal killing assay using baby rabbit complement (rSBA). Meningococcal polysaccharide
(PS) speciﬁc IgG and IgM concentrations were determined with a ﬂuorescent bead-based multiplex im-
munoassay.
Results: Lower post-vaccination functional antibody titers against meningococcal group W and Y were observed
in the middle-aged adults compared to the adolescents. One year post-vaccination, also a signiﬁcantly higher
proportion of the middle-aged adults possessed an rSBA titer below protection level. A large reduction in post-
vaccination IgM concentrations was observed in the middle-aged adults, whereas IgG concentrations were only
marginally diﬀerent between the two age groups.
Strong correlations between the post-vaccination rSBA titers and IgM concentrations were found both in the
middle-aged adults and the adolescents.
Conclusion: Although protective antibody titers were initiated after primary meningococcal vaccination in
middle-aged adults, antibody functionality was signiﬁcantly lower as compared to that in adolescents. This
diﬀerence was mainly caused by lower IgM responses. Our results indicate early signs of immune ageing in
middle-aged adults, which is important knowledge for the development of future vaccine strategies to better
protect elderly persons against infectious diseases.
1. Introduction
Prevention of infectious diseases in the elderly is important to es-
tablish healthy ageing in a rapidly ageing world population (Michel and
Lang, 2011; UnitedNations, 2015). Yet, eﬀective vaccine responses in
the elderly are often hampered by immunological ageing, leaving part
of the elderly vulnerable for infectious diseases (Lang and Aspinall,
2012). Timely vaccination of middle-aged adults, instead of elderly
persons, may be a solution to strengthen the memory immunity before
reaching old age (Michel and Lang, 2011; Rappuoli et al., 2011).
However, the immunological ﬁtness of the middle-aged adults is not
well-deﬁned.
Comparison of vaccine immunogenicity in middle-aged adults with
that in younger age groups is a valuable method in order to gain
knowledge on the early signs of immune ageing. Notwithstanding,
comparative studies are often biased by diﬀerences in pre-vaccination
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immunity between age groups, aﬀecting the vaccine induced responses.
This pre-vaccination immunity is frequently diﬀerent between old and
young participants due to diﬀerences in vaccine history or natural ex-
posure (Furman et al., 2013a, 2013b; Weinberger et al., 2013).
Therefore, de novo vaccine antigens should be used to describe diﬀer-
ences in vaccine responses between young and old (Michel and Lang,
2011; Lang and Aspinall, 2012).
In order to compare the vaccine immunogenicity between middle-
aged adults and a young age group, a primary tetravalent meningo-
coccal vaccination is employed, containing the meningococcal groups
A,C, W, and Y. Historical circulation of meningococci W (MenW) and
meningococci Y (MenY) in the Netherlands has been low (de Voer et al.,
2010), indicating that the vaccination will most likely induce primary
vaccine responses in both age groups. Of note, meningococci C (MenC)
is given as a booster response to the adolescents and therefore vaccine
responses cannot be compared between the age groups. Also compar-
ison of meningococci A (MenA) is diﬃcult due to interference of cross-
reactive antibodies in the assays. Meningococcal vaccine im-
munogenicity is highly studied in young children and adolescents,
whereas immunogenicity studies in older adults are scarce.
The highest numbers of meningococcal cases are observed in young
children (< 5 years) and adolescents. However, a peak of meningo-
coccal cases is also seen in older adults (65+), mainly caused by the
MenW and MenY (Diseases, 2005; Stoof et al., 2015; Edge et al., 2016).
During the currently ongoing MenW outbreak, a large proportion of the
cases is seen in the oldest age group (RIVM, 2017). Moreover, the
highest case fatality rate by meningococci is observed in the elderly
(Stoof et al., 2015).
We previously showed that a primary tetravalent meningococcal
vaccination induced protective, bactericidal antibody titers against
meningococcal group C, W, and Y in middle-aged adults (50–65 years of
age) that lasted for at least one year (Heiden et al., 2017). Moreover, we
demonstrated that the protective antibody titers against the de novo
antigens MenW and MenY were highly correlated with the meningo-
coccal speciﬁc IgM responses and that these IgM responses decreased
with age even in the limited age range of our study cohort (Heiden
et al., 2017).
In this study, the immunogenicity of a primary meningococcal
vaccination was compared between middle-aged adults and adolescents
(10–15 years of age) (van Ravenhorst et al., 2017a, 2017b). As ex-
pected, the meningococcal groups W (MenW) and Y (MenY) initiated a
clear primary immune response in the majority of the participants and
hence these meningococcal groups were used for comparison.
2. Methods
2.1. Study design and participants
This study combines data from two diﬀerent phase IV single center
and open-label studies. Both studies assessed the immunogenicity of a
primary tetravalent meningococcal vaccine conjugated to tetanus
toxoid (MenACWY-TT, Nimenrix, GlaxoSmithKline) either in adoles-
cents or in middle-aged adults (Heiden et al., 2017; van Ravenhorst
et al., 2017a, 2017b). The adolescents were vaccinated and sampled in
the spring of 2014 and the middle-aged adults in the autumn of 2014.
Detailed exclusion criteria of both studies have been previously de-
scribed (Heiden et al., 2017, van Ravenhorst et al., 2017a, 2017b). In
short, both the adolescents and middle-aged adults were excluded when
they showed signs of acute illness at the time of vaccination, used im-
mune suppressive medication, had allergies to vaccine components, had
a history of meningococcal disease or were administered a previous
tetravalent meningococcal vaccination. Written informed consent was
obtained from all participants and all procedures were in accordance
with the Declaration of Helsinki. The medical ethical committee:
Medical Research Ethics Committees United (MEC-U) approved the
studies and both studies were registered at the Dutch trial register
(adolescents: NTR4430; middle-aged adults: NTR4636).
2.2. Vaccination and blood sampling
A pre-vaccination blood sample was taken from all participants
before intramuscular administration of the tetravalent meningococcal
vaccine conjugated to tetanus toxoid vaccine (MenACWY-TT;
Nimenrix). Subsequently, blood samples were drawn at 28 days and at
1 year post-vaccination. Serum samples were collected using serum
clotting tubes (BD Biosciences) and were stored at−20 °C until further
use.
2.3. Serological analysis
Serological analyses were performed as previously described
(Heiden et al., 2017; van Ravenhorst et al., 2017a, 2017b). In short,
MenW and MenY PS-speciﬁc IgG and IgM concentrations were de-
termined with the ﬂuorescent bead-based-multiplex immunoassay
(MIA) (de Voer et al., 2009; Heiden et al., 2017; van Ravenhorst et al.,
2017a, 2017b). The MenW and MenY serum bactericidal antibody titers
were assessed using baby rabbit complement (rSBA) (Pelfreez,
LOT#13035EL) and the MP01240070 (MenW) and S-1975 (MenY)
strains, kindly donated by Prof. Dr. Ray Borrow from the Vaccine
Evaluation Unit at Manchester (PHE). The rSBA titer was deﬁned as the
highest serum dilution yielding ≥50% killing after 60 min of incuba-
tion at 37 °C (Maslanka et al., 1997). The internationally accepted level
of protection used was an rSBA titer ≥8, whereas a titer of ≥128 was
used as a more conservative protection level (Borrow et al., 2001).
Participants with an rSBA titer below the detection level of the assay
were considered seronegative, and were given an rSBA titer of 2 for
statistical purposes (Borrow et al., 2001; Borrow et al., 2005).
2.4. Statistics
Prior to all analyses, normal distribution of the data was checked.
The geometric mean rSBA titers (GMTs) and IgM/IgG concentrations
(GMCs) with the 95% conﬁdence intervals (95% CI) were presented.
The pre-vaccination rSBA GMTs as well as the pre-vaccination IgM and
IgG GMCs were compared with the Mann Whitney U test between the
adolescents and middle-aged adults. The 28 days and 1 year post-vac-
cination rSBA titers and IgM and IgG concentrations were log-trans-
formed to reach a normal distribution of the data. All post-vaccination
responses were compared between the adolescents and middle-aged
adults using linear regression, with adjustment for pre-vaccination va-
lues.
Moreover, the proportion of participants with an rSBA titer≥8 and
≥128 was calculated with the Wilson/Brown test and compared be-
tween the two groups with the Chi-squared test. The increase in rSBA
titers at 28 days post-vaccination was determined as: rSBA titer
28 days/rSBA titer pre-, whereas the antibody decay was determined as:
rSBA titer 1 year/rSBA titer 28 days.
All IgM and IgG analysis were performed on the total group of
participants as well as only on participants with an undetectable pre-
vaccination rSBA titer (rSBA = 2).
The correlations between the IgM and IgG concentrations with the
rSBA titers were determined with the Pearson's correlation test.
Graphpad Prism V7 and SPSS V22.0 were used for the statistical
analysis. A p-value < 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Participant characteristics
In total, blood samples from 225 adolescents (10–15 years of age)
and 204 middle-aged adults (50–65 years of age) were analyzed for PS-
speciﬁc IgG and IgM. The functional antibody titers (rSBA titers) were
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determined in all adolescent samples and in 100 middle-aged partici-
pants, as previously described (Heiden et al., 2017; van Ravenhorst
et al., 2017a, 2017b). Since rSBA titers were similar in the comparison
of the ﬁrst 50 and second 50 middle-aged participants, these 100
middle-aged adults have proven to be representative for these age
group. An overview of the samples used in this comparative study is
depicted in Fig. 1.
3.2. Lower MenW and MenY rSBA titers in middle-aged adults compared to
adolescents
Protective pre-vaccination rSBA titers (> 8) were found in a part of
participants (MenW: A: 15%, M: 23%, MenY: A: 32%, M: 27%)
(Table 1). Although low in both age groups, the pre-vaccination rSBA
geometric mean titers (GMTs) for MenY were signiﬁcantly lower in the
middle-aged adults than in the adolescents (p-value 0.046; Table1). No
signiﬁcant diﬀerence in pre-vaccination rSBA titer was found for MenW
between the two age groups (p-value 0.728; Table 1).
At 28 days post-vaccination, signiﬁcantly lower GMTs were found in
the middle-aged adults for both meningococcal groups (p-values <
0.001; Fig. 2a–b and Table 1), which was also reﬂected in a sig-
niﬁcantly lower antibody increase 28 days post-vaccination in the
middle-aged adults as compared to the adolescents (MenW p-value <
0.001 and MenY p-value = 0.008; Table 1). However, this lower an-
tibody response after 28 days did not result in a lower percentage of the
middle-aged adults reaching the rSBA protection titer of 8 (MenW p-
value = 0.599 and MenY p-value = 0.054; Table 1). Only a slightly
lower percentage of the middle-aged participants reached the more
conservative protection level of 128 for MenY (p-value = 0.018;
Table 1) than the adolescents.
At 1 year post-vaccination, a signiﬁcantly lower percentage of the
middle-age adults possessed an rSBA titer ≥8 against MenW (p-
value = 0.018) and MenY (p-value < 0.001) (Fig. 2a-b, and Table 1).
Next to the lower antibody increase 28 days post-vaccination, also a
signiﬁcant higher antibody decay was found in the middle-aged adults
for MenY after 1 year (p-value < 0.001) but not for MenW (p-
value = 0.484; Table 1).
The diﬀerences between the middle-aged adults and the adolescents
were slightly enlarged when comparing the pre-vaccination ser-
onegative persons only, at one month and one year post-vaccination
(Fig. 2c and d).
3.3. Lower MenW and MenY speciﬁc IgM responses in the middle-aged
adults
Although low in both groups, signiﬁcantly lower pre-vaccination
IgM concentrations were found for both MenW and MenY in the
middle-aged adults as compared to the adolescents (p-values < 0.001)
(Fig. 3a–b). After adjusting for the diﬀerences in pre-vaccination con-
centrations, signiﬁcantly lower post-vaccination IgM responses for
MenW and MenY were observed in the middle-aged adults than in the
adolescents (p-values < 0.001; Fig. 3a–b) both at 28 days and 1 year.
Similar results were obtained when only participants without detect-
able pre-vaccination rSBA titers (rSBA = 2) were analyzed (Fig. 3c–d).
The geometric mean IgM concentrations at the diﬀerent time points are
depicted in Supplementary Table 1.
3.4. Lower MenW and MenY speciﬁc IgG responses in middle-aged adults
Pre-vaccination, the middle-aged adults had signiﬁcantly lower
meningococcal speciﬁc IgG concentrations than the adolescents, for
both MenW and MenY (p-values < 0.001; Fig. 4a–b). After
Fig. 1. Cohort outline.
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adjustments for these diﬀerences in pre-vaccination IgG concentrations,
signiﬁcantly lower meningococcal group speciﬁc IgG responses were
found in the middle-aged adults 28 days post-vaccination for both
MenW (p-value = 0.001) and MenY (p-value = 0.01). This diﬀerence
persisted until 1 year post-vaccination for MenW (p-value = 0.004),
whereas, no signiﬁcant diﬀerence was observed in MenY IgG
concentrations after 1 year (p-value = 0.627) (Fig. 4a–b). Again, ap-
proximately similar results were found when only participants without
a detectable pre-vaccination rSBA titer (rSBA = 2) were compared
(Fig. 4c–d). The geometric mean IgG concentrations are depicted in
Supplementary Table 2.
Table 1
Comparison of the MenW and MenY rSBA titers in the adolescents and middle-aged adults.
MenW MenY
Adolescents Middle-aged p-value Adolescents Middle-aged p-value
Pre-
GMT [95% CI] 4.3 [3.4–5.4] 5.4 [3.8–7.8] 0.728 10.7 [7.8–14.6] 6.9 [4.5–10.4] 0.046
% rSBA≥ 8 [95% CI] 15.2 [11.1–20.5] 23.0 [15.8–32.2] 0.088 32.3 [26.5–38.7] 27.0 [19.3–36.4] 0.341
% rSBA≥ 128 [95% CI] 11.0 [7.6–15.7] 16.6 [10.0–23.6] 0.186 30.0 [24.4–36.4] 17.0 [10.9–25.5] 0.013
28 days
GMT [95% CI] 5790 [4829–6941] 1687 [1252–2272] < 0.001 3954 [3437–4550] 1448 [1026–2044] < 0.001
% rSBA≥ 8 [95% CI] 98.2 [95.5–99.3] 99.0 [94.6–99.9] 0.599 99.6 [97.6–100] 97.0 [91.5–99.2] 0.054
% rSBA≥ 128 [95% CI] 98.2 [95.6–99.3] 97.0 [91.5–99.1] 0.484 99.1 [96.8–99.8] 95.0 [88.8–97.8] 0.018
1 year
GMT [95% CI] 1165 [1006–1349] 330.8 [234.8–466.2] < 0.001 1331 [1114–1591] 247.3 [158.1–386.7] < 0.001
% rSBA≥ 8 [95% CI] 98.7 [96.1–99.6] 94.0 [87.5–97.2] 0.018 97.8 [94.9–99.1] 86.0 [77.9–91.5] < 0.001
% rSBA≥ 128 [95% CI] 98.7 [96.1–99.6] 88.0 [80.2–93.0] < 0.001 96.9 [93.7–98.5] 79.0 [70.0–85.8] < 0.001
Increase 28 days [95% CI] 1384 [1074–1783] 311 [200–485] < 0.001 393 [287–538] 209 [126.6–345] 0.008
Decay 1 year [95% CI] 0.20 [0.18–0.23] 0.19 [0.15–0.25] 0.484 0.33 [0.28–0.38] 0.16 [0.12–0.22] < 0.001
The pre-vaccination geometric mean titers (GMTs) between the two age groups were compared with the Mann Whitney U test. The GMTs at 28 days and 1 year post-vaccination were
compared using linear regression analysis with adjustment for pre-vaccination titers. The increase in rSBA titers at 28 days post-vaccination was determined as: rSBA titer 28 days/rSBA
titer pre-, whereas the antibody decay was determined as: rSBA titer 1 year/rSBA titer 28 days. The increase at 28 days, and the decay 1 year post-vaccination were compared between the
adolescents and middle-aged adults with the Mann Whitney U test. The proportions of participants with an rSBA titer above the protection levels of 8 and 128 were compared with the Chi
Squared test. Signiﬁcant diﬀerences are given in bold.
Fig. 2. MenW and MenY rSBA responses in adolescents and middle-aged adults.
Reverse cumulative distribution curves of the rSBA titers at the diﬀerent time points pre- and post-vaccination for the adolescents (A, blue) and middle-aged adults (M, red) for MenW (a
and c) and MenY (b and d). In panel a and b all participants (MenW: N= 224 A and N= 100 M, MenY: N= 223 A and N= 100 M) are represented whereas, panels c and d included
only participants without detectable pre-vaccination rSBA titers (MenW: N= 172 A, N= 76 M, MenY: N= 133 A and N= 73 M). The vertical lines represent the protection lines of
rSBA titers 8 and 128 respectively. Pre- = pre-vaccination, 28 d = 28 days post-vaccination, 1y = 1 year post-vaccination.
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3.5. Strong correlation between the post-vaccination rSBA titers and IgM
concentrations in both the middle-aged adults and the adolescents
Both in the middle-aged adults (MenW: R= 0.753, p < 0.001;
MenY: R= 0.707, p < 0.001) and adolescents (MenW: R= 0.801,
p < 0.001; MenY: R= 0.529, p < 0.001) high to moderate correla-
tions were observed between the post-vaccination rSBA titers and the
IgM concentrations (Fig. 5a–b). The correlations between the post-
vaccination rSBA titers and the IgG concentrations were low to mod-
erate in both the middle-aged adults (MenW: R= 0.342, p < 0.001;
MenY: R= 0.308, p < 0.001) and the adolescents (MenW: R= 0.359,
p < 0.001; MenY: R= 0.268, p < 0.001) (Fig. 5c–d). Our ﬁndings
suggest, as before (Heiden et al., 2017), that the functional antibody
titers after primary vaccination are mainly mediated by IgM.
4. Discussion
Within this comparative study, we showed that middle-aged adults
possessed lower antibody functionality up to one year after primary
meningococcal group W and Y vaccination in comparison with ado-
lescents. At 1 year post-vaccination, a signiﬁcantly higher percentage of
the middle-aged adults showed an rSBA titer below the protection level.
These lower bactericidal responses were mainly caused by lower IgM
responses in the middle-aged adults, although a slightly lower IgG re-
sponse was also observed with age.
We are the ﬁrst to compare the immunogenicity of the conjugated
meningococcal vaccine in older adults with that in a younger age group.
Of note, information about meningococcal vaccine immunogenicity in
middle-aged adults is scarce. However, some studies compared the
immunogenicity of the pneumococcal polysaccharide vaccine between
young adults (18–30 years of age) and elderly (64–88 years of age).
These studies found a reduced capacity in opsonizing pneumococci due
to a low IgM response in the elderly participants (Park and Nahm, 2011;
Leggat et al., 2013; Westerink et al., 2014), which is highly comparable
with our ﬁndings after primary meningococcal vaccination. In addition,
the pneumococcal vaccine primarily induced switched memory B cells
(CD27 + IgM-) in the elderly, whereas young participants mainly
showed increased CD27 + IgM+ cells (Leggat et al., 2013), likely
underlying the drop in IgM response with age. Nonetheless, these au-
thors found similar IgG responses in both age groups, which is not fully
in line with our ﬁndings of a slightly lower IgG response after primary
meningococcal vaccination in the middle-aged adults. This discrepancy
might be caused by diﬀerences in bacterial circulation between pneu-
mococci and meningococci, resulting in more frequent historical con-
tacts with pneumococci as compared to meningococci. Moreover, the
addition of a carrier protein in the meningococcal vaccine likely leads
to diﬀerent cellular immune responses compared to the plain poly-
saccharides for pneumococci, complicating a head to head comparison.
The lower IgM responses found in the middle-aged adults in our
study agree with the previously found decrease in total serum IgM
concentrations and numbers of IgM+ B–cells during chronological
ageing (Wu et al., 2012; Martin et al., 2015; Dunn-Walters, 2016).
These lower IgM responses largely aﬀect the antibody functionality at
advanced age, since IgM was previously shown to be highly functional
in complement binding and subsequently killing of the bacteria (Shyur
et al., 1992). This important role for IgM is also conﬁrmed by the sharp
drop in rSBA titers after depletion of serum IgM in the middle-aged
adults (Heiden et al., 2017). Importantly, these diminished IgM re-
sponses with age reduce the capacity to eﬀectively respond to primary
bacterial infections or vaccinations. On the contrary, the correlations
between the IgG concentrations and rSBA titers were low in both the
adolescents and the middle-aged adults, indicating less crucial roles for
Fig. 3. Lower MenW and MenY PS-speciﬁc IgM responses in the middle-aged adults as compared to the adolescents.
Comparison of the MenW (a and c) and MenY (b and d) PS-speciﬁc IgM responses between the adolescents (A,blue) and middle-aged adults (M,red). In a and b all participants were
compared, whereas participants without a detectable pre-vaccination rSBA titer (rSBA = 2) were compared in c and d. Pre-vaccination IgM concentrations were compared between the
adolescents and the middle-aged adults with the Mann Whitney U test, whereas IgM concentrations 28 days and 1 year post-vaccination were log transformed, after which linear
regression with adjustments for the pre-vaccination IgM concentrations was performed. ***p < 0.001.
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IgG in response to primary meningococcal vaccination. This notion is
totally diﬀerent after booster vaccinations where strong correlations
between the high IgG and rSBA responses were observed (van
Ravenhorst et al., 2017a, 2017b) and relatively low IgM concentrations
were found (data not shown). These ﬁndings suggest that the con-
tribution of IgG to the meningococcal antibody functionality depends
on the nature of the vaccine response, being either a primary or booster
vaccination.
In addition, we also observed faster antibody decay at 1 year post-
vaccination in the middle-aged adults as compared to the adolescents.
This ﬁnding suggests an age related diﬀerence in the formation and
survival of long-lived plasma cells, since long-term antibody production
is maintained by long-lived plasma cells residing in the bone marrow
(Manz et al., 1997). Others previously showed that fat deposition and
reduced production of survival factors in the bone marrow led to re-
duced survival of long-lived plasma cells at older age (Siegrist and
Aspinall, 2009; Pritz et al., 2014; Pritz et al., 2015; Pangrazzi et al.,
2017). Moreover, the homing of plasma cells towards the bone marrow
in order to become long-lived plasma cells was decreased with age
(Pritz et al., 2015). Subsequently, our data suggests that the age related
reduction in both the numbers of IgM+ B-cells and bone marrow
survival niches for long-lived plasma cells already aﬀect primary im-
mune responses to meningococcal antigens in middle-aged adults.
Furthermore, the T-cell help, as initiated by the tetanus toxoid
carrier protein, might have aﬀected the vaccine responsiveness. This T-
cell help may be diﬀerent between the two age groups, due to a distinct
tetanus vaccination history. Moreover, a shift in the T-cell compartment
from more naïve to senescent memory T-cells with age, as well as in-
creased numbers of regulatory T-cells (Arnold et al., 2011; den Braber
et al., 2012; Herndler-Brandstetter et al., 2013; Akbar et al., 2016), may
have diminished the T-cell response towards the carrier protein in the
middle-aged adults and subsequently have aﬀected the humoral
response, but this is currently unknown.
Remarkably, the diﬀerences between the adolescents and middle-
aged adults were enlarged when only seronegative participants were
compared. These results indicate that booster responses after natural
exposure are more immunogenic in middle-aged adults as compared to
primary immune responses. This ﬁnding is in agreement with others
who found large inﬂuences of pre-vaccination immunity on vaccine
responses in older adults (Furman et al., 2013a, 2013b; Weinberger
et al., 2013; Tsang et al., 2014).
Although the IgG and IgM concentrations in both age groups were
low before vaccination, we observed signiﬁcantly lower pre-vaccination
IgG and IgM concentrations in the middle-aged adults. This small dif-
ference between the two age groups might suggest a higher circulation
of meningococcal bacteria in the adolescents group, complying with the
general higher meningococcal carriage rates in adolescents
(Christensen et al., 2010; Borrow et al., 2017). This explanation is
strengthened by the signiﬁcantly higher pre-vaccination rSBA geo-
metric mean titer in the adolescents. Remarkably, the number of par-
ticipants with protective pre-vaccination titers was not diﬀerent be-
tween the two age groups. As a side note, this small diﬀerence might
also partly be explained by polyreactive antibodies, either IgM, IgG or
IgA, that can have antibacterial activity due to binding of distinct li-
gands, such as proteins, lipids and carbohydrates, without pathogen
speciﬁcity (Notkins, 2004; Zhou et al., 2007). Since sharp reductions of
these antibodies were found with age (Notkins, 2004), the adolescent
study group might possess higher quantities of these polyreactive an-
tibodies that might bind in small amounts to the bacterial poly-
saccharides and thereby possibly add to the explanation of the diﬀer-
ences in the pre-vaccination IgG and IgM concentrations. However, the
exact biological relevance of these antibodies is unknown (Notkins,
2004, Zhou et al., 2007).
Remarkably, a few individuals possessed suﬃcient speciﬁc
Fig. 4. Lower MenW and MenY PS-speciﬁc IgG responses in the middle-aged adults as compared to the adolescents.
Comparison of the MenW (a and c) and MenY (b and d) PS-speciﬁc IgG responses between the adolescents (A,blue) and middle-aged adults (M,red). In a and b all participants were
compared, whereas participants without a detectable pre-vaccination rSBA titer (rSBA = 2) were compared in c and d. The pre-vaccination IgG concentrations were compared between
the adolescents and the middle-aged population with the Mann Whitney U test, whereas IgG concentrations 28 days and 1 year post-vaccination were log transformed, after which linear
regression with adjustments for the pre-vaccination IgG titer was performed. *p < 0.05, **p < 0.01, ***p < 0.001.
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meningococcal antibody concentrations which were not functional in
the bacterial assay. Most likely these participants (mostly adults) pro-
duced enough speciﬁc anti-PS antibodies, but these antibodies fail in
functionality of aﬃnity or might be directed against less important
epitopes of the polysaccharides, also seen for pneumococcal antibody
levels in the elderly (Schenkein et al., 2008; Elberse et al., 2011).
Future studies will determine the long-term diﬀerences in the me-
ningococcal antibody levels between the middle-aged adults and the
adolescents. Nevertheless, based on the higher antibody decay rates
1 year post-vaccination, we hypothesize that these rates between the
two age groups will diverge even further, likely due to limited niches
available for long-lived plasma cells in the bone marrow of middle-aged
adults. Of importance, since the antibody functionality was highly de-
pendent on IgM responses, long-term protection by IgM is questionable.
Follow-up samples will enlarge our understanding of the IgM responses
and induction of memory B-cell responses on the antibody functionality
after primary vaccination. Moreover, the immunogenicity of booster
vaccination at elderly age is of interest for future study, after primary
vaccination at middle-age. This booster vaccination might be positively
inﬂuenced by the early induced pre-vaccination immunity, as also
shown for other vaccines (Weinberger et al., 2013).
In conclusion, although protective functional antibodies are ob-
tained in the middle-aged adults, the functional antibody titers after
primary meningococcal vaccination over a 1 year time period are sig-
niﬁcantly lower as compared to adolescents. Most importantly, higher
antibody decay was observed in the middle-aged adults, resulting in
lower numbers of protected middle-aged adults 1 year post-vaccination.
Large part of these diﬀerences between the adolescents and middle-
aged adults was explained by a sharp drop in the IgM response. This
reduced IgM response with age might indicate early signs of immune
ageing already in the middle-aged adults. Consequently, these results
are of importance for the development of future vaccine strategies for
the ageing population.
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